RedHill Biopharma Ltd. reported a registered direct offering of $1.25 million, selling 2,144,487 ADSs at $0.58289 each, which is a 10% premium over the closing price on March 28, 2024. The closing is expected on or about April 3, 2024, for general corporate purposes and working capital.